Progesterone receptor could slow breast cancer growth Researchers have discovered why breast cancer patients whose tumours display both oestrogen and progesterone receptors have the best chance of survival.…
Tracking down the optimum dose of exercise Prescribing physical activity could soon become as routine as prescribing drugs, and at least as beneficial.…
European Medicines Agency launches safety review of HPV vaccines A safety review of human papillomavirus vaccines, which protect young women against cervical cancer, has been launched by the European Medicines Agency.…
Methotrexate identified as potential treatment for blood cancers Researchers screened for drugs that inhibit metabolic pathway associated with myeloproliferative neoplasms.…
Erectile dysfunction drugs associated with increased melanoma risk Researchers have discovered a link between use of erectile dysfunction drugs and malignant melanoma, although they question whether the association is causal.…
Nivolumab granted positive scientific opinion under UK early access scheme Nivolumab, a new lung cancer drug, has been granted a positive scientific opinion by the UK medicines safety regulator under the Early Access to Medicines Scheme (EAMS).…
Panobinostat set for approval in Europe as multiple myeloma treatment The multiple myeloma drug panobinostat has received a positive opinion from the European Medicines Agency for the treatment of relapsed or refractory disease.…
Repositioning existing drugs for cancer treatment Scientists are using systematic approaches to identify non-oncology drugs that can be used to treat cancer, but access to drugs and commercial challenges are hindering progress.…
Nivolumab plus ipilimumab increases progression-free survival for melanoma patients Nivolumab alone or combined with ipilimumab results in longer progression-free survival than ipilimumab alone in patients with previously untreated metastatic melanoma.…
Modified herpes virus therapy shows promise in melanoma A virus-derived oncolytic immunotherapy has shown activity against melanoma in a phase III clinical trial, researchers report in the Journal of Clinical Oncology.…